
Chemistry - A European Journal p. 6859 - 6868 (2005)
Update date:2022-09-26
Topics:
Cui, Xiuhua
Fan, Yubo
Hall, Michael B.
Burgess, Kevin
Hydrogenation of 2,3-diphenylbutadiene (1) with the chiral carbene-oxazoline-iridium complex C has been studied by means of a combined experimental and computational approach. A detailed kinetic profile of the reaction was obtained with respect to consumption of the substrate and formation of the intermediate half-reduction products, 2,3-diphenylbut-1-ene (2) and the final product, 2,3-diphenylbutane (3). The data generated from these analyses, and from NMR experiments, revealed several facets of the reaction. After a brief induction period (presumably involving reduction of the cyclooctadiene ligand on C), the diene concentration declines in a zero-order process primarily to give mono ene intermediates. When all the diene is consumed, the reaction accelerates and compound 3 begins to accumulate. Interestingly, the prevalent enantiomer of the monoene intermediate 2 is converted mostly to meso-3 so the enantioselectivity of the reaction appears to reverse. The reaction seems to be first-order with respect to the catalyst when the catalyst concentration is less than 0.0075 M; diffusion of hydrogen across the gas-liquid interface complicates the analysis at higher catalyst concentra tions. Similarly, these diffusion effects complicated measurements of reaction rate versus applied pressure of dihydrogen; other factors like stir speed and flask geometry come into play under some, but not all, the conditions examined. Density functional theory (DFT) calculations, using the PBE method, were used to probe the reaction. These studies indicate a transoid-η 4-diene-di-hydride complex forms in the first stages of the catalytic cycle. Further reaction requires dissociation of one alkene ligand to give a η4-diene-dihydride-dihydrogen intermediate. A catalytic cycle that features Ir3+/Ir5+ seems to be involved thereafter.
View MoreWuxi D-Stone International Co., Ltd.
Contact:+86-510-82740567
Address:21F Hengtong Int'l Centre, 215Zhongshan Road, Wuxi, Jiangsu,China
Jiangxi Huashi Pharmaceutical Co., Ltd
Contact:+86-795-4509628
Address:Ningbo Ave., Fengtian Industrial Park, Fengxin Country, Jiangxi, China.
Contact:+86-10-62651721
Address:29 Yongxing Road, Daxing District,Beijing China
Angelisun(Chongqing) Pharmaceutical Co., LTD.
Contact:+86-23-68030926-816
Address:D1-7 Tech & Entrepreneurs Park, Kecheng Road, Erlang Hi-Tech Areas, Chongqing, China
Anhui Biochem United Pharmaceutical Co., Ltd.
Contact:0086 551 5167062 / 5228268
Address:No. 30 Hongfeng Road, Hi-Tech Development Zone, Hefei (230088), China
Doi:10.1055/s-1977-24478
(1977)Doi:10.1002/jps.2600660826
(1977)Doi:10.1021/jo00324a042
(1981)Doi:10.1021/jo01298a030
(1980)Doi:10.1055/s-2003-41470
(2003)Doi:10.1016/j.tet.2016.07.014
(2016)